Gliomas can be characterized by several pathological molecular changes, including telomerase reverse transcriptase promoter mutations, isocitrate dehydrogenase mutations, methylguanine methyltransferase promoter methylation, 1p/19q codeletion and alpha thalassemia retardation syndrome X-linked (ATRX) mutations [2]. This evidence concerns the gene ATRX and central nervous system cancer.